{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "17552923",
  "DateCompleted": {
    "Year": "2007",
    "Month": "07",
    "Day": "11"
  },
  "DateRevised": {
    "Year": "2015",
    "Month": "11",
    "Day": "19"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1744-8387",
      "JournalIssue": {
        "Volume": "4",
        "Issue": "3",
        "PubDate": {
          "Year": "2007",
          "Month": "Jun"
        }
      },
      "Title": "Expert review of proteomics",
      "ISOAbbreviation": "Expert Rev Proteomics"
    },
    "ArticleTitle": "NMR-based metabolomics approach to target biomarkers for human prostate cancer.",
    "Pagination": {
      "StartPage": "389",
      "EndPage": "400",
      "MedlinePgn": "389-400"
    },
    "Abstract": {
      "AbstractText": [
        "In the era of genomics and proteomics, metabolomics offers a unique way to probe the underlying biochemistry of malignant transformations. In the context of oncological metabolomics, the study of the global variation of metabolites involved in the development and progression of cancers, few existing techniques offer as much potential to discover biomarkers as nuclear magnetic resonance techniques. The most fundamental magnetic resonance methodologies with regard to human prostate cancer are magnetic resonance spectroscopy and magnetic resonance spectroscopic imaging. Recent in vivo explorations have examined crucial metabolites that may indicate cancerous lesions and have the potential to direct treatment; while ex vivo studies of prostatic fluids and tissues have defined novel diagnostic parameters and indicated that magnetic resonance methodologies will be paramount in future prostate cancer management."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Massachusetts General Hospital, Molecular Pathology, Charlestown, MA 02129, USA. kcrocker@nmr.mgh.harvard.edu"
          }
        ],
        "LastName": "Jordan",
        "ForeName": "Kate W",
        "Initials": "KW"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Cheng",
        "ForeName": "Leo L",
        "Initials": "LL"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Expert Rev Proteomics",
    "NlmUniqueID": "101223548",
    "ISSNLinking": "1478-9450"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Biomarkers, Tumor"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "analysis"
      ],
      "DescriptorName": "Biomarkers, Tumor"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Magnetic Resonance Imaging"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Magnetic Resonance Spectroscopy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "diagnosis",
        "metabolism"
      ],
      "DescriptorName": "Prostatic Neoplasms"
    },
    {
      "QualifierName": [
        "methods",
        "trends"
      ],
      "DescriptorName": "Proteomics"
    }
  ],
  "NumberOfReferences": "105"
}